SOON.SW
Strong BuyPremium GrowerAI neutralSonova Holding AG · Healthcare · Switzerland · $17.4B
CHF 251.60 +1.3% · close 5 Oct · scored 7 Oct
Premium Grower: Strong business with the market behind it, priced at a premium.
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Sonova is one of the world's leading hearing-aid makers, in a concentrated industry with high returns on capital, strong brands and a long demographic tailwind from ageing populations. The quality is clear. There is no new catalyst, however: the forward earnings consensus slipped 1.9% in four weeks, and over-the-counter hearing aids and consumer audio competitors pressure the lower end of the market.
ABOUT SONOVA HOLDING AG
Read
Sonova Holding AG is a global leader in hearing care solutions, developing, manufacturing, and distributing a comprehensive portfolio of hearing aids, cochlear implants, and wireless communication devices under brands like Phonak and Advanced Bionics. The company maintains a strong competitive moat through its continuous innovation, extensive R&D investments, and a broad intellectual property portfolio that spans complex audiological technologies. Its vertically integrated model, encompassing both product development and a significant retail audiological network, reinforces its dominant market position worldwide.
FINANCIAL SUMMARY (CHF)
| Year | 2022 | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.4B | 3.7B | 3.6B | 3.6B | 3.6B | 1.8% | 3.6B | 3.8B | 4.1B | 6.6% |
| EPS (CHF) | 10.42 | 10.75 | 10.08 | 9.07 | 7.23 | -8.7% | 9.05 | 7.33 | 8.15 | 6.2% |
| Shares | 63.2M | 59.6M | 59.6M | 59.6M | 59.4M | -6.0% | 59.4M | — | — | — |
| Debt | 1.5B | 1.8B | 1.8B | 1.8B | 1.7B | 3.6% | 1.7B | — | — | — |
| Equity | 2.4B | 2.2B | 2.5B | 2.7B | 2.6B | 2.0% | — | — | — | — |
| Op CF | 941.1M | 783.9M | 753.3M | 790.3M | 734.5M | -6.0% | 709.9M | — | — | — |
| Inv CF | -705.9M | -428.3M | -234.0M | -201.6M | -182.1M | — | — | — | — | — |
| Fin CF | -1.4B | — | — | -399.7M | -451.3M | — | — | — | — | — |
Calmer than 77% of stocks we rank over the past year (28% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SOON.SW are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SOON.SW | Sonova Holding AG(you) | $17.4B | 80 | Strong Buy |
| MOVE.SW | Medacta Group SA | $2.8B | 40 | Hold |
| NVCR | NovoCure Limited | $1.9B | 41 | Hold |
| MED.SW | Medartis Holding AG | $1.3B | 39 | Hold |
| STMN.SW | Straumann Holding AG | $18.8B | 73 | Buy |
| METN.SW | Metall Zug AG | $469M | 44 | Hold |
| KURN.SW | Kuros Biosciences AG | $845M | 28 | Sell |
| ONC | BeOne Medicines AG | $41.3B | 83 | Strong Buy |
| MTD | Mettler-Toledo International Inc. | $29.9B | 70 | Buy |
| YPSN.SW | Ypsomed Holding AG | $5.7B | 70 | Buy |
Peer medians: ROE 10.8% · P/E 32.3x · Gross margin 62.5%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.